What is it about?
The in vitro activities of two novel azole compounds (aryl-1,2,4-triazol- 3-ylthio analogues of fluconazole [ATTAFs]) and five comparator antifungal agents against 52 clinical Candida isolates from 5 different species were determined. The novel azole compounds had the lowest geometric mean MICs, followed by fluconazole. Moreover, combinations of these compounds with fluconazole exhibited synergistic effects against fluconazole-susceptible (22 of 23 isolates), fluconazole-susceptible dose-dependent (10 of 13 isolates), and fluconazole-resistant (1 of 16 isolates) Candida isolates.
Featured Image
Why is it important?
to determine the in vitro activity of ATTAF-1 and ATTAF-2, in comparison with five clinically important antifungal drugs, against fluconazole-susceptible and -resistant Candida isolates. Moreover, we investigated the combination of these compounds with fluconazole
Perspectives
Further analysis of the differences between different compounds and fluconazole could elucidate the underlying mechanisms of action. In conclusion, although ATTAF-1 and ATTAF-2 exhibited potent activities against clinical Candida isolates, their effectiveness, alone or in combination with fluconazole, for the treatment of Candida infections needs to be determined; in addition, the underlying mechanisms of action should be investigated
Dr Hamid Badali
Mazandaran University of Medical Sciences
Read the Original
This page is a summary of: In Vitro Activities of Novel Azole Compounds ATTAF-1 and ATTAF-2 against Fluconazole-Susceptible and -Resistant Isolates of Candida Species, Antimicrobial Agents and Chemotherapy, October 2016, ASM Journals,
DOI: 10.1128/aac.01106-16.
You can read the full text:
Contributors
The following have contributed to this page
